Zhao Y, Li J, Ma S, et al. - This study was conducted among acute coronary syndrome (ACS) patients complicated with anemia receiving percutaneous coronary intervention, to assess how long‐term prognosis in these patients could be impacted by extended dual antiplatelet therapy (DAPT) beyond 12 months. From the Optimal anti Platelet Therapy for Chinese patients with Coronary Artery Disease (OPT‐CAD) study, overall 6,953 patients were enrolled in this study. Major adverse cardiovascular and cerebrovascular events (defined as a composite of all‐cause death, myocardial infarction, and stroke) were assessed as the primary outcome. According to findings, a decrease in stroke incidence without any elevation in bleeding risk may be provided by extended DAPT beyond 12 months in anemic ACS patients who tolerate 12‐month DAPT.